Medical articles today

/* 728x15, */

Birth Of Blood-Forming Stem Cells In Embryo Imaged By Biologists

Biologists at UC San Diego have identified the specific region in vertebrates where adult blood stem cells arise during embryonic development. Their discovery, which appears in a paper in this week's early online edition of the journal Nature, is a critical first step for the development of safer and more effective stem cell therapies for patients with leukemia, multiple myeloma, anemia and a host of other diseases of the blood or bone marrow. The researchers say their time-lapse imaging of the process, by which primitive embryonic tissues first produce the parent stem cells that produce all adult blood cells over the life of an individual, should help guide future efforts to repair and replace this cell population for therapeutic purposes.

Biologics, Inc. Selected To Provide Pharmacy Management Services In National Marrow Donor Program Clinical Trial

Biologics, Inc., the leading cancer management company in the United States, announces that its Oncology Clinical Trial Services division has been selected by the National Marrow Donor Program® (NMDP), a nonprofit organization that facilitates unrelated hematopoietic cell transplants. Biologics' Oncology Clinical Trial Services division is providing pharmacy management services for an NMDP Phase III trial that is determining the safety and efficacy of filgrastim (Neupogen® )-stimulated peripheral blood stem cells (PBSC) in hematopoietic cell transplants involving unrelated donors. The trial is also investigating the effects of the donation process on the unrelated stem cell donors.

/* 468x60, */

PARI Pharma Enrolls First Patient In Phase 2b Study Of L-CsA

PARI Pharma has enrolled the first patient in its Phase 2b clinical trial studying inhaled liposomal cyclosporine A (L-CsA) delivered via a customized Investigational eFlow Nebulizer System. The multinational study is investigating the safety and efficacy of PARI's L-CsA formulation. In previous clinical trials, reactions from physicians and lung transplant recipients to PARI's drug-device combination were encouraging. "We are very pleased to move forward with this investigational treatment aimed at preventing bronchiolitis obliterans, which is an incurable small airway disease in lung transplant recipients. This study has been designed with advice from the European Medicines Agency under L-CsA's orphan drug designation status, " said Manfred Keller, chief scientific officer and executive vice president of PARI Pharma.

Medium Term Outcome Of Laparoscopic Sacrocolpopexy With Xenografts Compared To Synthetic Grafts - Graft materials are increasingly being used to improve surgeries for pelvic floor prolapse, in an effort to reduce recurrence. There is some evidence this is indeed so, but a number of graft related complications (GRC) cause clinically relevant problems (erosion, pain, dyspareunea) and may lead to reintervention. This may be the consequence of an inappropriately balanced response of the host to the implant. One potentially causative factor for GRC is the choice of implant material. The most widely used product today is polypropylene, in an open construct with pores large enough to allow in growth of tissue by the host. As an alternative "biologic" matrices have been proposed.

Acutely Damaged Livers May Be Repaired Via Transplanted Hepatocytes

A research team from the National Taiwan University Hospital has evaluated the efficiency of transplanted hepatocyte (liver) cells in animal models severely damaged by two kinds of chemical toxicity to see whether and how transplanted hepatocytes were able to efficiently repopulate the toxin-induced, severely damaged livers. The results of this study are published in the current double issue of Cell Transplantation (18:10/11) and are freely available on-line at The study was carried out in the on-going effort to evaluate hepatocyte transplantation as an alternative to liver transplantation, not only because of the current shortage of liver donors for transplantation, but also because successful cell transplantation is simpler, less invasive and less expensive than organ (i.

/* 468x60, */

Immune Cell Levels Predict Skin Cancer Risk In Kidney Transplant Patients

Measuring certain types of immune cells may predict the high risk of skin cancer after kidney transplantation, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). "There are differences in the immune system, and some of these are associated with the development of skin cancer after transplantation, " comments Robert Carroll, MD (The Queen Elizabeth Hospital, Woodville, South Australia). The researchers measured levels of key immune cells in 116 kidney transplant recipients, 65 of whom developed squamous cell skin cancers. "We were hoping to see if there were differences in the immune systems of patients who developed skin cancer after transplantation compared to those who did not develop skin cancer, " says Carroll.

/* 160x600, */
Medical articles today © Padayatra Dmitriy
Designer Dimitrov Dmytriy